---
title: "Viva Biotech climbs 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303350862.md"
description: "Viva Biotech rose 6.35% to HK$1.340. Down 25.56% YTD."
datetime: "2026-10-28T07:59:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303350862.md)
  - [en](https://longbridge.com/en/news/303350862.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303350862.md)
generator: "portal-rs"
---

# Viva Biotech climbs 6%

Viva Biotech (1873.HK) climbed more than **6%** in Hong Kong trading to **HK$1.34**.

The stock is down 25.56% year to date and sits 28.85% above its 52-week low of HK$1.040.

The Hang Seng Index is down 2.33% over the past five sessions and down 9.87% year to date.

The life sciences tools and services industry index rose 3.2% over the same period; the stock outperformed the index by 3.1 percentage points.

Guosen Securities initiated coverage on the company with a Buy rating, forecasting revenue of 2.054 billion yuan, 2.535 billion yuan and 3.13 billion yuan for 2026 through 2028, respectively. Net income is projected at 191 million yuan, 261 million yuan and 353 million yuan over the same period.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [01873.HK](https://longbridge.com/en/quote/01873.HK.md)

## Related News & Research

- [10:57 ETViva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth](https://longbridge.com/en/news/297064309.md)
- [Viva Biotech grants 6.22 million RSUs to CDMO staff at HK$ 1.08 each](https://longbridge.com/en/news/290927873.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [Moonshot drops $150M Indonesia Nvidia rental days after US loophole crackdown](https://longbridge.com/en/news/306145817.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**